EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

Clinical trial NCT05619913 · COMPLETED

Trial details

NCT number: NCT05619913
Sponsor: Australia New Zealand Gynaecological Oncology Group
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Carcinosarcoma Uterine Carcinosarcoma

Start date: 2023-05-22
Primary completion: 2025-03-31
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.